| Autor: |
Trafalis, Dimitrios T. P., Tsavdaridis, Dimitrios, Camoutsis, Charalambos, Karayiani, Venetia, Mourelatos, Dionysios, Chrysogelou, Eleni, Dalezis, Panayotis, Athanassiou, Athanasios, Pangalis, Gerassimos A., Papageorgiou, Athanasios |
| Předmět: |
|
| Zdroj: |
British Journal of Haematology; Feb2005, Vol. 128 Issue 3, p343-350, 8p |
| Abstrakt: |
NSC290205 (A) is an hybrid synthetic antineoplastic ester that is a combination of ad-lactam derivative of androsterone and an alkylating derivative ofN,N-bis(2-chloroethyl)aniline. We tested NSC290205 for synergistic antileukaemic activity with adriamycin (ADR), (i)in vitroagainst the human lymphoid leukaemia cell lines: CCRF-CEM, MOLT-4, and RPMI-8226, (ii)in vivoagainst P388 lymphocytic and L1210 lymphoid murine leukaemias (at incipient and advanced phase). Our results indicated significant cytostatic and cytotoxic synergy of NSC290205 and ADRin vitro. We further examined these resultsin vivoby replacing cyclophosphamide in the standard CHOP (cyclophosphamide, hydroxydaunomycin, Oncovin, prednisone) regimen with NSC290205 (AHOP) and comparing the efficiency of these two regimensin vivo. Although treatment of P388 and L1210 with cyclophosphamide or NSC290205 alone yielded equivalent results, AHOP produced a clear benefit for survival compared with CHOP against advanced leukaemias, confirming thein vitroobservations [higher percentage increase in median lifespan of treated animals over the untreated (control): 188% and 239% in L1210, 308% and 353% in P388,P < 0·01, for CHOP and AHOP respectively]. AHOP also proved to be more genotoxic and cytostatic than CHOP, inducing higher sister chromatid exchange levels and cell division delays on P388 cellsin vivo. NSC290205 showed superior antineoplastic potential against lymphoid leukaemia and significant synergy with ADR, producing an excellent therapeutic outcome. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text